Inventor · disambiguated record
Thomas Horn-Spirohn
Also filed as: HORN-SPIROHN THOMAS
3 granted patents·9 pending applications·10 citations·filing 2013–2023
60Inventor score
Top patents by PatentIndex Score
12 records- 0186US10328066B2Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancerNOVARTIS AG·Filed 2016·Granted Jun 25, 2019·5 cites·2 claims
- 0283US9867825B2Pharmaceutical combination comprising binimetinibNOVARTIS AG·Filed 2013·Granted Jan 16, 2018·5 cites·12 claims
- 0370US2023398115A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0461US2021260059A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0557US2021186973A1Combination of ribociclib and dabrafenib for treating or preventing cancerNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0654US2019060309A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2016·Application pending·0 cites
- 0744US2018250302A1Combination of ribociclib and dabrafenib for treating or preventing cancerCAPONIGRO GIORDANO·Filed 2016·Application pending·0 cites
- 0839US2018318275A1Combination therapy using pi3k inhibitor and mdm2 inhibitorNOVARTIS AG·Filed 2016·Application pending·0 cites
- 0936US10328065B2Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancerNOVARTIS AG·Filed 2016·Granted Jun 25, 2019·0 cites·3 claims
- 1034US2018243304A1Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancerNOVARTIS AG·Filed 2016·Application pending·0 cites
- 1134US2019365741A1Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancerNOVARTIS AG·Filed 2016·Application pending·0 cites
- 1230US2018256557A1Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancerCAPONIGRO GIORDANO·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas Horn-Spirohn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →